Hashim, DanaHaber, Philipp K.Dinani, AmreenSchiano, Thomas D.Asgharpour, AmonKushner, TatyanaKakked, GauravTabrizian, ParissaSchwartz, MyronGurakar, AhmetDieterich, DouglasBoffetta, PaoloFriedman, Scott L.Llovet, Josep MariaSaberi, Behnam2022-05-062022-05-062020Puigvehí M, Hashim D, Haber PK, Dinani A, Schiano TD, Asgharpour A, et al. Liver transplant for hepatocellular carcinoma in the United States: evolving trends over the last three dècades. Am J Transplant. 2020 Jan; 20(1): 220-30. DOI: 10.1111/ajt.155761600-6135http://hdl.handle.net/10230/53011Hepatitis C virus infection has been the most common etiology in HCC-related liver transplantation (LT). Since 2014, direct-acting antivirals (DAAs) have dramatically improved HCV cure. We aimed to study the changing pattern of etiologies and impact in outcome in HCC-related LT according to HCV treatment-era through retrospective analysis of the Scientific Registry of Transplant Recipients (SRTR) database (1987-2017). A total of 27 855 HCC-related liver transplants were performed (median age 59 years, 77% male). In the DAA era (2014-2017) there has been a 14.6% decrease in LT for HCV-related HCC; however, HCV remains the most common etiology in 50% of cases. In the same era, there has been a 50% increase in LT for NAFLD-related HCC. Overall survival was significantly worse for HCV-related HCC compared to NAFLD-related HCC during pre-DAA era (2002-2013; P = .031), but these differences disappeared in the DAA era. In addition, HCV patients had a significant improvement in survival when comparing the DAA era with IFN era (P < .001). Independent predictors of survival were significantly different in the pre-DAA era (HCV, AFP, diabetes) than in the DAA era (tumor size). HCV-related HCC continues to be the main indication for LT in the DAA era, but patients' survival has significantly improved and is comparable to that of NAFLD-related HCC.application/pdfengThis is the peer reviewed version of the following article: Puigvehí M, Hashim D, Haber PK, Dinani A, Schiano TD, Asgharpour A, et al. Liver transplant for hepatocellular carcinoma in the United States: evolving trends over the last three dècades. Am J Transplant. 2020 Jan; 20(1): 220-30, which has been published in final form at http://dx.doi.org/10.1111/ajt.15576. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.info:eu-repo/semantics/articlehttp://dx.doi.org/10.1111/ajt.15576Clinical research/practiceLiver diseaseInfectiousLiver disease: malignantLiver transplantation/hepatologyinfo:eu-repo/semantics/openAccess